Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
Associated Therapies
-

Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients

First Posted Date
2014-07-11
Last Posted Date
2023-01-30
Lead Sponsor
Mclean Hospital
Target Recruit Count
227
Registration Number
NCT02188121
Locations
🇺🇸

McLean Hospital, Belmont, Massachusetts, United States

Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients

First Posted Date
2014-06-24
Last Posted Date
2014-06-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
363
Registration Number
NCT02172586

Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2014-04-23
Last Posted Date
2017-02-10
Lead Sponsor
Anthony J Viera, MD, MPH
Target Recruit Count
28
Registration Number
NCT02121041
Locations
🇺🇸

University of North Carolina, Chapel Hill, North Carolina, United States

Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis

First Posted Date
2014-02-14
Last Posted Date
2015-07-01
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
720
Registration Number
NCT02063100
Locations
🇨🇳

National Clinical Research Center for Kidney Disease, State Key Laboratory of Kidney Disease, Department of Nephrology, Chinese PLA General Hospital, Beijing, Beijing, China

🇨🇳

Beijing Friendship,Capital Medical University, Beijing, Beijing, China

🇨🇳

Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, Beijing, China

and more 40 locations

Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System

First Posted Date
2013-12-13
Last Posted Date
2015-12-22
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Target Recruit Count
120
Registration Number
NCT02010905
Locations
🇳🇱

Academic Medical Center, Amsterdam, Netherlands

🇳🇱

St Antonius ziekenhuis, Nieuwegein, Netherlands

🇳🇱

Universitair Medisch Centrum Groningen, Groningen, Netherlands

and more 3 locations

A Study of Muscle Strength Maintenance in Older Adults

Phase 2
Completed
Conditions
Interventions
First Posted Date
2013-11-21
Last Posted Date
2018-06-12
Lead Sponsor
Johns Hopkins University
Target Recruit Count
37
Registration Number
NCT01989793
Locations
🇺🇸

Johns Hopkins Bayview Clinical Research Unit, Baltimore, Maryland, United States

Losartan for Sickle Cell Kidney Disease

Early Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-11-20
Last Posted Date
2017-07-17
Lead Sponsor
Emory University
Target Recruit Count
24
Registration Number
NCT01989078
Locations
🇺🇸

Children's Healthcare of Atlanta, Atlanta, Georgia, United States

🇺🇸

Grady Health Systems, Atlanta, Georgia, United States

Cardiomyopathy in DMD: Lisinopril vs. Losartan

First Posted Date
2013-11-13
Last Posted Date
2017-03-21
Lead Sponsor
Nationwide Children's Hospital
Target Recruit Count
23
Registration Number
NCT01982695
Locations
🇺🇸

University of California Davis, Davis, California, United States

🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

🇺🇸

St. Louis Children's Hospital, St. Louise, Missouri, United States

and more 3 locations

Comparision of Blood Pressure Variability Between Amlodipine and Losartan

Phase 4
Completed
Conditions
Interventions
First Posted Date
2013-10-17
Last Posted Date
2017-05-12
Lead Sponsor
Wonju Severance Christian Hospital
Target Recruit Count
144
Registration Number
NCT01964079
Locations
🇰🇷

Wonju Severance Christian Hospital, Wonju, Gangwon-do, Korea, Republic of

Study of Losartan in the Treatment of NAFLD in Children

Phase 2
Completed
Conditions
Interventions
First Posted Date
2013-08-01
Last Posted Date
2017-05-15
Lead Sponsor
Miriam Vos, MD
Target Recruit Count
12
Registration Number
NCT01913470
Locations
🇺🇸

Emory University / Children's Healthcare of Atlanta, Atlanta, Georgia, United States

© Copyright 2024. All Rights Reserved by MedPath